Pay vs Performance Disclosure - USD ($)

12 Months Ended

Dec. 31, 2024

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Pay vs Performance Disclosure

Pay vs Performance Disclosure, Table

Year	Summary Compensation Table Total for PEO(1) ($)	Compensation Actually Paid to PEO(1),˒(2),˒(3) ($)	Average Summary Compensation Table Total for Non-PEO NEOs(1) ($)	Average Compensation Actually Paid to Non-PEO NEOs(1),(2),(3) ($)	Value of Initial Fixed $100 Investment based on:(4)		Net Income ($ Millions)	Net Revenue(5) ($ Millions)
					TSR ($)	Peer Group TSR ($)
(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)
2024	6,417,897	7,623,575	2,207,895	2,425,045	44.32	81.12	5.8	235.1
2023	10,573,359	14,915,528	3,892,438	5,271,052	44.37	88.90	(78.0)	175.5
2022	8,837,397	(8,899,595)	3,275,710	(748,376)	21.32	90.18	(108.2)	134.0
2021	1,240,389	16,344,707	718,163	4,188,759	112.88	118.47	(181.0)	45.6
2020	10,678,868	(2,601,908)	3,233,747	2,545,959	68.26	128.55	(102.7)	50.1

Company Selected Measure Name

et revenue

Named Executive Officers, Footnote

Peter Greenleaf was our PEO for each year presented.

PEO Total Compensation Amount

$ 6,417,897

$ 10,573,359

$ 8,837,397

$ 1,240,389

$ 10,678,868

PEO Actually Paid Compensation Amount

$ 7,623,575

14,915,528

(8,899,595)

16,344,707

(2,601,908)

Adjustment To PEO Compensation, Footnote

Compensation actually paid reflects the exclusions and inclusions of certain amounts for the PEO and the non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards and Option Awards column are the totals from the Stock Awards and Option Awards columns set forth in the Summary Compensation Table.

(4)The peer group total shareholder return (“TSR”) set forth in this table utilizes the Russell 3000 Biotech Index. The comparison assumes $100 was invested for the period starting December 31, 2019, through the end of the listed year in the Company and in the Russell 3000 Biotech Index, respectively. Historical stock performance is not necessarily indicative of future stock performance.

(5)We determined net revenue to be the most important financial performance measure used to link Company performance to compensation actually paid to our PEO and non-PEO NEOs in 2024. This performance measure may not have been the most important financial performance measure for years 2021 and 2020 and we may determine a different financial performance measure to be the most important financial performance measure in future years.

Reconciliation of Summary Compensation Table to Compensation Actually Paid

Year	Summary Compensation Table Total for Peter Greenleaf ($)	Exclusion of Stock Awards and Option Awards for Peter Greenleaf ($)	Inclusion of Equity Values for Peter Greenleaf ($)	Compensation Actually Paid to Peter Greenleaf ($)
	(a)	(b)	(c)	(d) = (a) + (b) + (c)
2024	6,417,897	(4,825,917)	6,031,596	7,623,575
2023	10,573,359	(8,999,997)	13,342,166	14,915,528
2022	8,837,397	(7,502,011)	(10,234,980)	(8,899,595)
2021	1,240,389	—	15,104,318	16,344,707
2020	10,678,868	(9,288,898)	(3,991,878)	(2,601,908)
Year	Average Summary Compensation Table Total for Non-PEO NEOs ($)	Average Exclusion of Stock Awards and Option Awards for Non-PEO NEOs ($)	Average Inclusion of Equity Values for Non-PEO NEOs ($)	Average Compensation Actually Paid to Non-PEO NEOs ($)
	(a)	(b)	(c)	(d) = (a) + (b) + (c)
2024	2,207,895	(1,280,605)	1,497,755	2,425,045
2023	3,892,438	(3,023,431)	4,402,045	5,271,052
2022	3,275,710	(2,375,417)	(1,648,669)	(748,376)
2021	718,163	—	3,470,596	4,188,759
2020	3,233,747	(2,741,071)	2,053,283	2,545,959

Non-PEO NEO Average Total Compensation Amount

$ 2,207,895

3,892,438

3,275,710

718,163

3,233,747

Non-PEO NEO Average Compensation Actually Paid Amount

$ 2,425,045

5,271,052

(748,376)

4,188,759

2,545,959

Adjustment to Non-PEO NEO Compensation Footnote

The individuals comprising the non-PEO NEOs for each year presented are listed below.

2024	2023	2022	2021	2020
Joe Miller	Joe Miller	Joe Miller	Joe Miller	Joe Miller
Max Donley	Max Donley	Max Donley	Max Donley	Max Donley
Stephen Robertson	Stephen Robertson	Stephen Robertson	Stephen Robertson	Stephen Robertson
Scott Habig	Volker Knappertz	Max Colao	Max Colao	Max Colao
Greg Keenan		Volker Knappertz		Dennis Bourgeault
		Neil Solomons

Compensation actually paid reflects the exclusions and inclusions of certain amounts for the PEO and the non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards and Option Awards column are the totals from the Stock Awards and Option Awards columns set forth in the Summary Compensation Table.

(4)The peer group total shareholder return (“TSR”) set forth in this table utilizes the Russell 3000 Biotech Index. The comparison assumes $100 was invested for the period starting December 31, 2019, through the end of the listed year in the Company and in the Russell 3000 Biotech Index, respectively. Historical stock performance is not necessarily indicative of future stock performance.

(5)We determined net revenue to be the most important financial performance measure used to link Company performance to compensation actually paid to our PEO and non-PEO NEOs in 2024. This performance measure may not have been the most important financial performance measure for years 2021 and 2020 and we may determine a different financial performance measure to be the most important financial performance measure in future years.

Reconciliation of Summary Compensation Table to Compensation Actually Paid

Year	Summary Compensation Table Total for Peter Greenleaf ($)	Exclusion of Stock Awards and Option Awards for Peter Greenleaf ($)	Inclusion of Equity Values for Peter Greenleaf ($)	Compensation Actually Paid to Peter Greenleaf ($)
	(a)	(b)	(c)	(d) = (a) + (b) + (c)
2024	6,417,897	(4,825,917)	6,031,596	7,623,575
2023	10,573,359	(8,999,997)	13,342,166	14,915,528
2022	8,837,397	(7,502,011)	(10,234,980)	(8,899,595)
2021	1,240,389	—	15,104,318	16,344,707
2020	10,678,868	(9,288,898)	(3,991,878)	(2,601,908)
Year	Average Summary Compensation Table Total for Non-PEO NEOs ($)	Average Exclusion of Stock Awards and Option Awards for Non-PEO NEOs ($)	Average Inclusion of Equity Values for Non-PEO NEOs ($)	Average Compensation Actually Paid to Non-PEO NEOs ($)
	(a)	(b)	(c)	(d) = (a) + (b) + (c)
2024	2,207,895	(1,280,605)	1,497,755	2,425,045
2023	3,892,438	(3,023,431)	4,402,045	5,271,052
2022	3,275,710	(2,375,417)	(1,648,669)	(748,376)
2021	718,163	—	3,470,596	4,188,759
2020	3,233,747	(2,741,071)	2,053,283	2,545,959

Compensation Actually Paid vs. Total Shareholder Return

Compensation Actually Paid vs. Net Income

Tabular List, Table

List of Most Important Financial Performance Measures

Net revenue was the sole financial performance measure that the Company used in linking compensation actually paid to our PEO and other NEOs for 2024 to Company performance.

Total Shareholder Return Amount

$ 44.32

44.37

21.32

112.88

68.26

Peer Group Total Shareholder Return Amount

81.12

88.90

90.18

118.47

128.55

Net Income (Loss)

$ 5,800,000

$ (78,000,000.0)

$ (108,200,000)

$ (181,000,000.0)

$ (102,700,000)

Company Selected Measure Amount

235,100,000

175,500,000

134,000,000.0

45,600,000

50,100,000

PEO Name

Peter Greenleaf

Additional 402(v) Disclosure

The amounts shown for compensation actually paid have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by the Company’s NEOs. These amounts reflect the Summary Compensation Table Total with certain adjustments as described in footnote 3 below.

Measure:: 1

Pay vs Performance Disclosure

Compensation Actually Paid vs. Other Measure

PEO | Measure:: 1

Pay vs Performance Disclosure

Name

Net revenue

PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

$ (4,825,917)

$ (8,999,997)

$ (7,502,011)

$ 0

$ (9,288,898)

PEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

6,031,596

13,342,166

(10,234,980)

15,104,318

(3,991,878)

PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

7,425,760

8,999,997

2,799,360

0

7,762,704

PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(30,559)

1,566,255

(5,421,035)

10,202,439

(7,270,230)

PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

0

0

0

0

0

PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(1,363,605)

2,775,914

(7,613,305)

4,901,879

(4,484,352)

PEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

0

0

0

0

0

PEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

$ 0

0

0

0

0

Non-PEO NEO | Measure:: 1

Pay vs Performance Disclosure

Name

Net revenue

Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

$ (1,280,605)

(3,023,431)

(2,375,417)

0

(2,741,071)

Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

1,497,755

4,402,045

(1,648,669)

3,470,596

2,053,283

Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

1,924,311

3,023,431

701,513

0

2,449,340

Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(15,673)

616,428

(656,801)

2,255,191

(235,061)

Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

0

0

0

0

95,426

Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(410,883)

762,186

(941,151)

1,215,405

(256,422)

Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

0

0

(752,230)

0

0

Non-PEO NEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

$ 0

$ 0

$ 0

$ 0

$ 0